Parkinson`S Disease Equipment & Supplies

The antibody PD1602 is targeting alpha-synuclein for treatment of Parkinson’s disease. The aim is to develop a disease modifying treatment that stops or slows down disease progression. The project is conducted in collaboration with ...

The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease ...

We are developing mGlu4 PAM as a novel orally available treatment for Parkinson's disease. We are currently optimizing multiple chemical series of highly selective mGlu4 PAMs with compounds in early lead ...

In cooperation with SUNY Upstate Medical University, Quadrant Biosciences is developing a non-invasive, saliva biomarker test highly accurate in characterizing Parkinson’s disease through an evaluation of human and oral microbiome transcripts ...

Clinical studies are planned in 2021 to demonstrate the efficient transdermal delivery of a well-established Parkinson's disease ...

Parkinson's disease is predominantly a movement disorder resulting from degeneration of dopaminergic neurons in the substantia nigra. The cause of the disease is unknown, but substantial evidence suggests that the aggregation of α-synuclein is a critical step in the etiology of Parkinson's disease (PD). ...

Levodopa Cyclops™ is a levodopa dry powder inhaler for the fast and reliable relief of OFF episodes in Parkinson’s disease. As such, Levodopa Cyclops™ answers a major unmet medical need. Levodopa is the cornerstone in the treatment of Parkinson’s disease for well over 50 ...

After more than a decade of research, Professor Grill's lab discovered a way to 'speak' to the area of the brain that controls movement in people with Parkinson's disease. The stimulation patterns were designed to be more effective and/or more energy efficient than standard ...

mGlu2 NAM for the treatment of mild neurocognitive disorders, or mNCD. We are developing mGlu2 NAM as a novel orally available treatment for mNCD associated with Alzheimer’s disease, Parkinson’s disease and depressive disorders. The program is in clinical candidate selection phase and we expect to ...

α-Synuclein is a major component of Lewy bodies in the affected neurons in Parkinson's disease. This protein has a mass of 14.5 kDa (140 amino acids long) and consists of a conserved degenerative amino-terminal domain and an acidic carboxyl-terminal with higher sequence divergence. α-Synuclein is predominantly expressed in brain, specifically in ...

When tau proteins become defective, It will result in the self-assembly of tangles in brain and increased some neurodegenerative diseasesincluding Alzheimer’s disease (AD)?Pick's disease?Parkinson's disease (PD)?Progressive supranuclear palsy(PSP) and Corticobasal degeneration ...

This belt-worn on-body drug delivery device for small-molecule drugs has been developed for our pharma partner EVER Pharma. The wearable device is used by Parkinson's disease patients for the administration of apomorphine to treat this long-term degenerative disorder of the central nervous system. This device is customizable to be used with suitable other drugs ...

The KinesiaU™ motor assessment system serves as a clinically validated, cost-effective prescription application designed for individuals managing Parkinson’s disease and essential tremor. This innovative system is compatible with both iPhone and Android smartphones, as well as smartwatches, allowing users to systematically track core symptoms including tremors, ...

It allows the wearer to say goodbye to cumbersomeness and uncomfortableness. In the future, it will be a life assistant for patients with stroke, spinal paralysis, arthritis, Parkinson's disease, and the ...

The soft exoskeleton is not limited to helping stroke patients. In the future, it can be used in cerebral palsy, Alzheimer's disease (senile dementia), multiple sclerosis, Parkinson's disease, and mobility problems in the elderly. When the muscles do not have enough power to make people walk, the soft and lightweight Easywalk™ can help ...

Alkahest, with its partner Grifols, is developing lead clinical candidates, GRF6019 and GRF6021, as potential treatments for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease with cognitive impairment. Designed to safely replenish regenerative positive ...

The complex and the peptides within it are viewed as having potential utility in neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral ...

Motion features are translated into biomarkers to provide objective information about movement abnormalities which support diagnosis and monitoring of Parkinson's disease and other impairments. Full audit trail of results. Full monitoring of changes over time. Patented and CE marked as a medical device. Manufacturing setup with QMS according to all relevant ...

Protein aggregation is a major pathological feature of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). Under pathological conditions, Tau, Amyloid beta, alpha-synuclein, TDP-43, Huntingtin and other proteins ...

Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). This is a ...